Research programme: immunomodulator therapeutics - Realm Therapeutics

Drug Profile

Research programme: immunomodulator therapeutics - Realm Therapeutics

Alternative Names: PR 031; PR023; RLM 023

Latest Information Update: 06 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Puricore
  • Developer Realm Therapeutics
  • Class Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acne vulgaris
  • Research Inflammation

Most Recent Events

  • 27 Feb 2018 Realm therapeutics receives notice of patent allowance for a patent entitled "Methods and Compositions for Treating Inflammatory Disorders," for the treatment of inflammation associated with Type II or Type III hypersensitivity reactions from the USPTO
  • 15 Feb 2018 Realm Therapeutics intends to file an IND application with the US FDA for a phase II trial of RLM 023 in Acne vulgaris during fourth quarter of 2018
  • 16 Oct 2017 Preclinical trials in Acne vulgaris in USA (Topical) before October 2017 (Realm Therapeutics pipeline, October 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top